1,3-Dihydro-1-isopropenyl-2H-imidazo<4.5-b>pyridinon-(2) | 20934-70-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 1,3-Dihydro-1-isopropenyl-2H-imidazo<4.5-b>pyridinon-(2)
• 英文别名: 1-(propan-2-yl)-1H,2H,3H-imidazo[4,5-b]pyridin-2-one；1-propan-2-yl-3H-imidazo[4,5-b]pyridin-2-one
• CAS: 20934-70-7
• 化学式: C₉H₁₁N₃O
• 分子量: 177.206
• InChiKey: AUWZZSGSVLYKIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• CGRP Receptor Antagonists
  申请人：Luo Guanglin

  公开号：US20090258866A1

  公开（公告）日：2009-10-15

  The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

  本公开通常涉及公式I的新化合物，包括它们的盐，这些盐是CGRP受体拮抗剂。本公开还涉及用于治疗CGRP相关疾病，包括偏头痛和其他头痛、神经源性血管扩张、神经源性炎症、热损伤、循环性休克、与更年期相关的潮红、气道炎症性疾病如哮喘和慢性阻塞性肺病（COPD）的药物组合物和方法。
• CGRP receptor antagonists
  申请人：Gutierrez Corey

  公开号：US20080004261A1

  公开（公告）日：2008-01-03

  The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.

  本发明涉及CGRP受体拮抗剂，其药物组成物，以及用于治疗CGRP受体介导的疾病和症状的方法。
• Spirolactam Bicyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090325991A1

  公开（公告）日：2009-12-31

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式：（其中变量A1、A2、A3、A4、A5、A6、A7、B、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• Bicyclic Anilide Spirolactam Cgrp Receptor Antagonists
  申请人：Bell M. Ian

  公开号：US20080096878A1

  公开（公告）日：2008-04-24

  The present invention is directed to compounds of Formula (I): (where variables A 1 , A 2 , B, J, K, m, n, R 4 , R 5a , R 5b and R 5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及公式（I）的化合物：（其中变量A1、A2、B、J、K、m、n、R4、R5a、R5b和R5c的定义如本文所述），该化合物可用作CGRP受体拮抗剂，并可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。